Expression of costimulatory molecular CD80 and CD86 in Raji cells and HL-60 cells induced by trichostatin A and the relationship with immunity

Abstract

Listen

Translate article

Objective To investigate trichostatin A (TSA)-induced costimulatory molecular CD80 and CD86 expressions of Raji and HL-60 cells as well as the relationship with immune response. Methods The proliferative activities of Raji cells and HL-60 cells were assessed by morphology and methyl thiazolyl tetrazolium (MTT) assay. The expressions of CD80 and CD86 were confirmed, and cell viability was examined by flow cytometer after 150 nmol/L TSA treatment. The expression status of CD80 mRNA and CD86 mRNA was analyzed by reverse transcription polymerase chain reaction (RT-PCR). Results A time- and dose-dependent inhibition was detected in Raji cells and HL-60 cells treated with TSA. The expression of CD80 in Raji cells for 12, 24, and 48 h was(76.2±4.6)%, (78.7±6.9)%, and (79.2±3.4)%, respectively. After TSA (150 nmol/L) treatment for 12h, 24h, and 48 h, the expression of CD80 was[(82.4±7.2)%, t=2.56, P=0.47],[(84.8±5.6)%, t=2.57, P=0.42], and[(93.9±8.7)%, t=2.67, P=0.38]in Raji cells, respectively. The CD80 mRNA expression was 0.45±0.32 in control group. After TSA (150 nmol/L) treatment in Raji cells for 12, 24, and 48h, the CD80 mRNA expression was (0.49±0.22, t=2.45, P=0.47), (0.76±0.33, t=3.67, P=0.0071), and (0.85±0.34, t=4.25. P=0.0048), respectively. The expression of CD86 in HL-60 cells for 12h, 24h, and 48 h was (28.8±5.3)%, (29.6±6.3)%, and (29.2±1.4)%. After TSA (150 nmol/L) treatment for 12, 24, and 48 h, the expression of CD86 was[(38.5±4.3)%, t=2.87, P=0.37],[(42.9±7.1)%, t=3.01, P=0.32], and[(61.4±9.7)%, t=4.56, P=0.0076], respectively. The CD86 mRNA expression was 0.52±0.16 in control group. After TSA (150 nmol/L) treatment in HL-60 cells for 12h, 24h, and 48 h, the CD86 mRNA expression was (0.63±0.45, t=2.67, P=0.42), (0.75±0.61, t=3.97, P=0.0078), and (0.92±0.36, t=5.01, P=0.0032), respectively. Conclusions TSA induces costimulatory molecular CD80 and CD86 expression of Raji and HL-60 cells, improves immune response of cells, and provides a novel immunotherapy of ant-malignancy hematological disease. Key words: Hydroxamic acids/PD; Lymphoma, non-hodgkin/PA/IM/DT; HL-60 cells/PA/IM/DE; Antigens, CD80/DE; Antigens, CD86/DE